Brief: Innate Pharma H1 Net Result Turns To Loss Of EUR 10.3 Mln

Innate Pharma SA

08/09/2020 06:10

Sept 8 (Reuters) - Innate Pharma SA  IPH.PA :
    * REG-INNATE PHARMA REPORTS FIRST HALF 2020 FINANCIAL
RESULTS AND
BUSINESS UPDATE
    * CASH POSITION OF EUR 184.6 MILLION AS OF JUNE 30, 2020
    * INNATE RESUMED ENROLLMENT OF LACUTAMAB TELLOMAK PHASE 2
CLINICAL
TRIAL FOR PATIENTS WITH SÉZARY SYNDROME AND MYCOSIS FUNGOIDES
    * INNATE TO EXPLORE AVDORALIMAB IN INFLAMMATION BEYOND
COVID-19
    * MONALIZUMAB PHASE 3 STUDY EXPECTED TO INITIATE IN THE
SECOND
HALF OF 2020, TRIGGERING $50 MILLION MILESTONE PAYMENT
    * NET LOSS OF EUR 10.3M FOR FIRST HALF OF 2020 (NET INCOME
OF EUR
13.2M FOR FIRST HALF OF 2019)
    * OPERATING EXPENSES OF EUR 46.0M IN FIRST HALF OF 2020 (EUR
45.9M
IN H1
    * REVENUE AND OTHER INCOME AMOUNTED TO EUR 36.7M IN FIRST
HALF OF
2020 (EUR 59.2M IN FIRST HALF OF 2019)
    * PHASE 3 TRIAL EVALUATING MONALIZUMAB IS EXPECTED TO
COMMENCE IN
SECOND HALF OF 2020
    * INNATE EXPECTS TO START SHARING DATA FROM THIS TRIAL FOR
MYCOSIS
FUNGOIDES IN 2021 AND SÉZARY SYNDROME IN 2022

Source text for Eikon:  ID:nGNE5Ndfp7 
Further company coverage:  IPH.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))